Crk-like (CrkL) adapter protein inhibitors and methods of making and using same
By developing Crk-like adaptor protein inhibitors such as citronella tincture and its derivatives, which specifically block CrkL phosphorylation, the problem of not being able to simultaneously inhibit tumor growth and restore immune cell function in existing technologies has been solved, achieving the effect of selectively inhibiting cancer cell proliferation and prolonging mouse survival.
Patent Information
- Application Number
- CN202380032723.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-01
- Filing Date
- 2023-02-01
- Publication Date
- 2024-11-22
AI Technical Summary
The lack of existing drugs that can specifically block the function of Crk-like adaptor proteins means that tumor growth cannot be effectively inhibited and the function of depleted immune cells cannot be restored.
Crk-like adaptor protein inhibitors have been developed, particularly citronella oleracea and its derivative compound IV, which selectively inhibit tumor cell growth without affecting immune cell function by directly inhibiting CrkL phosphorylation and blocking its signal transduction pathway.
These compounds significantly inhibited the proliferation of various cancer cell lines and prolonged survival time in mouse xenograft models, without affecting immune cell function, demonstrating good preclinical safety and therapeutic potential.
Smart Images

Figure CN119013271A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 305,354, filed on February 1, 2022, which is incorporated herein by reference in its entirety. Technical Field
[0003] The present disclosure relates to Crk-like adaptor protein inhibitors and methods of use thereof.
[0004] Thank you for the government's support
[0005] This invention was made with government support under Grant No. 1R01AI130197-01A1 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art
[0006] The Crk adaptor family of proteins plays a key role in tumorigenesis, cancer metastasis and immune response. Phosphorylation of Crk is involved in tumor metastasis and natural killer (NK) cell inhibition and depletion. In theory, simultaneous blocking of phosphorylation of Crk in tumor cells and immune cells (pCrk) will inhibit tumor growth and metastasis, and restore the effective immune response of exhausted immune cells against tumors. Therefore, there is a need in the art for Crk-like adaptor protein inhibitors. Summary of the invention
[0007] Disclosed herein are compound embodiments selected from the group consisting of:
[0008]
[0009] Also disclosed are embodiments of therapeutically effective compositions comprising one or more of the compounds and a pharmaceutically acceptable carrier.
[0010] The disclosed compounds can be used to inhibit or prevent tumor growth without inhibiting immune cell function.Also disclosed are method embodiments for inhibiting Crk-mediated signaling pathways, comprising exposing a sample or individual to a compound according to any or all of the above embodiments or a therapeutically effective composition thereof.
[0011] Also disclosed are embodiments of methods of enhancing immune cell responses in an individual suffering from or suspected of suffering from a chronic viral infection or cancer, comprising administering to the individual a compound according to any or all of the above embodiments, or a therapeutically effective composition thereof.
[0012] The foregoing and other objects and features of the present disclosure will become more apparent from the following detailed description made with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figures 1A-1D The results of the Alpha assay as described herein are shown, wherein Figure 1A A representative detection schematic is shown using the Alpha assay, which uses two beads: nickel-coated donor beads that bind his-tagged Crk, and anti-rabbit IgG-coated acceptor beads. Abl phosphorylation of CrkL (Tyr207) can be detected with an anti-pCrkL antibody (rabbit IgG). Each bead contains a different proprietary mixture of chemicals that are key elements of the Alpha technology. The donor beads contain the photosensitizer phthalocyanine, which converts ambient oxygen into an excited and reactive form, singlet oxygen, when irradiated at 680nm. With its 4μsec half-life, singlet oxygen can diffuse approximately 200nm in solution. If an acceptor bead is within this distance, energy is transferred from the singlet oxygen to a dimethylthiophene derivative within the acceptor bead, resulting in the production of light at 520-620nm. Modified by PerkinElmer; Figure 1B Results are shown for five libraries as indicated, which were screened and plotted as a function of normalized intensity for each AlphaScreen (two experiments). Pomiferin (also referred to herein as NC5) was identified from the NCI Natural Products and Natural Compounds (NC) library (in purple); Figure 1C It is shown that the pCrkL antibody demonstrates an increase in emission intensity in a dose-dependent manner; and Figure 1D Eight promising hits (#5-12) from the NC library are shown. Gleevec, which blocks the interaction between Abl and Crk, was used as a positive control. DMSO, vehicle control.
[0014] Figures 2A-2D The results of evaluating the binding of NC5 to CrkL are shown, where Figure 2A Schematic diagram showing the principle of thermal drift: proteins will denature at elevated temperatures, and this denatured state can be detected by the presence of a fluorescent dye (Sypro Orange is used here). Candidate chemicals that can bind to the protein will stabilize the protein and lead to a higher denaturation temperature. The midpoint value of the stability curve is characterized as the melting temperature (T m ); Figure 2B Representative examples of NC5 binding to CrkL are shown, where the top curve (after a temperature of 50°C) represents CrkL alone (no drug) and the bottom curve (after a temperature of 50°C) represents CrkL+NC5; Figure 2C and 2D CrkL( Figure 2C ) and Abl( Figure 2D) Statistical analysis of thermal drift of . 71 candidate drugs were screened using thermal drift assays for both CrkL and Abl. Proteins were either "CrkL" or "Abl" only. More than two centralities were defined as positive results. Each drug was screened three times for each protein.
[0015] Figures 3A-3C Results of evaluating candidate compounds using an in vitro kinase assay are shown, wherein Figure 3A Lane 1 is a marker, lane 2 (CrkL only) represents a blank control, lane 3 (CrkL+Abl) represents a negative control, lane 4 (Gleevec treatment) represents a positive control, and lanes 5 to 13 represent the results of CrkL+Abl+the indicated compounds. Anti-CrkL antibody detects protein expression; Figure 3B , use with Figure 3A Similar loading design, but detected by anti-phosphor-CrkL antibody (pTyr207); Figure 3C Relative kinase inhibition efficiency based on CrkL and fluorescent CrkL expression by in vitro kinase assay is shown. Expression of both CrkL and fluorescent-CrkL in the negative control was arbitrarily set to "1", and other treatments were compared to the negative control. pCrkL and CrkL were set as the phosphorylation ratio, while kinase inhibition potency was set as (1-pCrkL / CrkL)×100%.
[0016] Figures 4A-4D Results using the smFRET assay design are shown, where Figure 4A and 4B A schematic diagram of the assay design is shown, illustrating that CrkL is site-specifically labeled with donor (light lines) and acceptor (dark lines) FRET dyes. For surface immobilization, 6xHis-labeled CrkL is added to a biotinylated 6xHis antibody bound to streptavidin, which is adsorbed on a quartz slide. The quartz surface is passivated using a lipid bilayer. When indicated, the immobilized Crk is phosphorylated in situ. In the absence of Abl kinase or in the presence of a pCrk inhibitor (e.g., a compound embodiment of the present disclosure), the non-phosphorylated open conformation CrkL generates a low smFRET ( Figure 4A ); Figure 4B It is shown that in the presence of Abl, phosphorylated closed conformation pCrkL generates high FRET; Figure 4C Examples of donor (light line) and acceptor (dark line) intensities for site-specifically labeled CrkL are shown, showing high FRET (top) and low FRET (bottom); Figure 4DActual smFRET data are shown, indicating that phosphorylation reduces the distance between the SH2 and SH3C domains of Crk. FRET is high in the presence of Abl (line labeled "CrkL+Abl") but without its inhibitor Gleevec, and is reduced (line labeled "CrkL+Abl+Gleevec") in the presence of Gleevec, positive control (upper panel), and NC5 (lower right panel).
[0017] Figures 5A-5E The results of analyzing breast cancer cells as described herein are shown, wherein Figure 5A Results of three breast cancer cell lines Hs578t, MDA-MB-231 (MDA-231) and MDA-MB-468 (MDA-468) treated with DMSO (1:4000), Gleevec (2.5 μM) and NC5 (2.5 μM) for 48 hours are shown, and cell proliferation is measured by MTT. Gleevec (p=0.05) and NC5 (p=0.0009) both significantly inhibited cell proliferation of Hs578T cells (upper figure); NC5 (p=0.02) inhibited cell proliferation of MDA-MB-231 cells, but Gleevec (p=0.27) did not (middle); NC5 (p=0.02) inhibited cell proliferation of MDA-MB-468 cells, but Gleevec (p=0.99) did not (lower figure); Figure 5B PBMCs from three healthy donors were treated with DMSO, Gleevec and NC5 overnight before being applied to the IL2 ELISA assay. Neither Gleevec nor NC5 inhibited IL2 secretion in donor 1 (upper panel), donor 2 (middle panel) and donor 3 (lower panel); Figure 5C and 5D It was shown that breast cancer cells were more sensitive to aurantium flavone treatment than PMBC and leukemia cells, where Figure 5D In the figure, the lines with symbols ▼, ◆, ▲ and ● represent TNBC cells (MDA-MB-231, BT549 and Hs578T), and the lines with symbols ● and ■ represent non-TNBC cells (MCF7 and MDA-MB-453). Peripheral blood mononuclear cells (PBMC, lines with symbols □) were used to determine the specificity of the cytotoxic effect of aurantium flavonoids. The survival curves of the PBMC-average values were from four different healthy donors. Cells (1×10 3 -3×10 3 ) were plated in 96-well plates, and cell growth was determined by MTT assay 3 days after cells were treated with the indicated doses of aurantiacum. The IC50 of aurantiacum against each cell line was calculated by ComboSyn, Inc., the publisher of Compusyn software; Figure 5EShown are the results of treating K562, NK92-MI, Daudi, KHYG-1, PBMC, and MDA-231-LUC cells with 5 μM aurantium for 3 days and determining cell growth by MTT assay.
[0018] Figure 6 Shown are the structures of compounds disclosed herein, including auranthus serratus (also referred to herein as NC5), Compound II, and Compound III. The structures of all modified products have been submitted for confirmation by mass spectrometry (MS).
[0019] Figures 7A-7C The results show that MDA-MB-231 cells ( Fig. 7A ) and BXPC3 cells ( Figure 7B ) results, in which different concentrations of NC5 or compound II (in Figures 7A-7C Cells were treated with 5 μM NC5-SO2F (referred to as "NC5-SO2F") and viability was determined by MTT assay. Compound II had increased toxicity in MDA-231 and BXPC3 cells at 5 μM; Figure 7C Shown is the viability of BXPC3 cells confirmed by PI staining with NC5 or Compound II.
[0020] Figures 8A-8C The results show that MDA-MB-231 cells ( Fig. 8A ) or BXPC3 cells ( Figure 8B ) results, in which 5uM NC5, compound III (in Figures 8A-8C "NC5-140-1" in Figures 8A-8C Cells were treated with NC5-140-2 (referred to as "NC5-140-2" in the literature) for 24-48 hours, where cell viability was determined using the XTT assay. Symbols indicate significance of NC5 vs. Compounds I and / or III; *p<0.05. Data represent mean ± SEM, N=3; Figure 8C Shown are Sk-Hepl cells treated with 5uM of the disclosed compounds for 24 hours, and cell culture images demonstrate growth inhibition by the disclosed compounds.
[0021] Figures 9A-9F Results using certain compound embodiments in mice are shown, wherein Fig. 9A Shown in NSG TM Results of a xenograft model of TNBC generated in mice using MDA-MB-231 (MDA-231-LUC) cells expressing firefly luciferase. When tumor size reached 20 mm (2.0 cm), mice were sacrificed and dissected at the endpoint. Five mice were used per group. The line with the symbol ● represents vehicle (0.5% ); The line with the symbol ■ represents Gleevec (imatinib mesylate, 40 μg / g) treatment; the line with the symbol ▲ represents aurantiacum fructone (5 μg / g) treatment. The asterisk near each such line indicates the significance of vehicle vs. Gleevec or the significance of Gleevec vs. aurantiacum fructone. *p<0.05, **p<0.005, ***p<0.0005 on the indicated treatment days. Statistically significant by two-way ANOVA multiple comparisons. Data represent mean ± SEM. N=5; Fig. 9B Survival of mice bearing orthotopic xenograft tumors of MDA-231-LUC after treatment with vehicle (●), Gleevec (■) or auranthus serratus (▲) is shown. The p-values for vehicle vs. Gleevec, vehicle vs. auranthus serratus, and Gleevec vs. auranthus serratus were 0.0173, 0.0025, and 0.0025, respectively. The p-values were determined by Log-rank (Mantel-Cox) test (n=5 mice / group). The median survival of vehicle, Gleevec, and auranthus serratus was 25 days, 28 days, and 41 days, respectively; Fig. 9C The body weight of mice is shown, showing the toxicity of vehicle (●), Gleevec (■) or aurantia odoriferum (▲) treatment and the general health of the animals. The significant difference between vehicle vs. aurantia odoriferum groups on day 23 indicates that the tumor mass itself reached 1.5 to 2 g in the vehicle-treated group. The significant weight difference between the Gleevec group vs. aurantia odoriferum group was on day 27; Fig.9D 4 to 6 week old female non-obese diabetic / severe combined immunodeficiency (NOD / SCID) patient-derived xenograft (PDX) tumor-bearing mice were obtained, which were subcutaneously implanted with P1-P3 fragments of human patient-derived breast cancer xenograft TM00089 (Jackson Laboratory) for aurantiacum treatment studies. The mice were randomly divided into two groups of 5-6 mice each. When the tumor size reached 20 mm (2.0 cm), the mice were dissected at the endpoint. The line with the symbol ● represents the vehicle (0.5% ), the line with symbol ■ represents aurantia serrata (5 μg / g) treatment. Mice were monitored and tumor growth was recorded twice a week by caliper measurement. The p value for vehicle vs. aurantia serrata was < 0.0001. The p value was determined by two-way ANOVA test (n = 5-6 mice / group); Fig.9E Shown is the survival of mice bearing PDXTM 00089 tumors after treatment with vehicle (●) and auranthus serratus (■). The p-value for vehicle vs. auranthus serratus is 0.0025. The p-value was determined by Log-rank (Mantel-Cox) test (n=5-6 mice / group). The median survival for vehicle and auranthus serratus was 39 days and 53 days; Fig.9FShown are the body weights of the mice, indicating the toxicity of vehicle (●) and aurantiacum (■) treatments and the general health of the animals.
[0022] Figures 10A-10D The results show that NC5 significantly inhibited tumor growth in Sk-Hep1 xenograft mice; Fig. 10A Shown is the survival rate of SK-Hep1 xenograft tumors in mice after NC5 treatment; Fig. 10C NC5 was shown to significantly reduce tumor size in BXPC3 xenograft mice; Fig. 10D NC5 was shown to increase survival in the BXPC3 mouse model.
[0023] Figures 11A-11D The results of treatment with embodiments of the compounds disclosed herein are shown to inhibit HCC and breast tumor growth and prolong mouse survival in two xenograft mouse models; Fig.11A NC5 and compound embodiments of the present disclosure (Compounds III and I, referred to as "NC5-140-1" and "NC5-140-2," respectively) are shown to inhibit tumor growth in Sk-Hepl xenograft mice; Fig. 11B Shows increased survival of mouse SK-Hep1 xenograft tumors after NC5 treatment and treatment with compounds III and I; Fig. 11C NC5 or Compound III was shown to reduce tumor size in the 4T1 orthotopic mammary mouse model; Fig.11D It was shown that both NC5 and Compound III significantly increased the survival rate of an orthotopic breast cancer mouse model.
[0024] Figures 12A-12D Results of a test are shown in which blood samples were collected from mice treated for 20 days with vehicle, Gleevec (40 μg / g), low-dose auranthus feroxanthin (5 μg / g), and high-dose auranthus feroxanthin (20 μg / g). Three mice were treated in each group. Before and after treatment (20 days), blood samples were collected from each mouse, and serum was obtained for alanine aminotransferase (ALT, SGPT, Fig. 12A ), aspartate aminotransferase (AST, SGOT, Fig. 12B ), blood urea nitrogen (BUN, Fig. 12C ) and creatinine ( Fig.12D ) tests to monitor liver and kidney toxicity. The normal reference range for ALT is 17-77 IU / L; AST is 54-298 IU / L; BUN is 18.5-33.3 mg / dL; Cr is 0-0.40 mg / dL. The results showed that treatment with aurantiacum serrata at the indicated doses and Gleevec caused little or no damage to the liver or kidneys during the treatment period in mice.
[0025] Figures 13A-13DResults obtained after 6 days of treatment of MDA-MB-231-LUC cells with 3 μM aurantiacum or without treatment (control) are shown. Total cellular CrkL or phosphor-CrkL was labeled with Alexa Fluor 647 (AF-647) and stained with a secondary antibody conjugated to AF-647 as a staining control. Fig.13A Flow cytometric analysis results of mean fluorescence intensity (MFI) of the AF-647 fluorescence channel are shown, with each cell labeled with the indicated number; Fig. 13B The results of Western blot examination of the basal levels of pCrkL and CrkL in MDA-231, MDA-468 and HepG2 cells are shown, using PBMC cells from normal donors as a comparison. The pCrkL level in tumor cells is much higher than that in PBMC; Fig. 13C Results after 24 hours of treatment of MDA-468 or PBMC with various concentrations of NC5 are shown. Cells were harvested and stained with Annexin V-FITC / PI and then measured by flow cytometry; NC5 significantly increased apoptosis in MDA-468 cells. But had little effect in PBMC; Fig.13D The apoptotic effect of NC5 in MDA-231 and MDA-468 cells is shown, summarized in the bar graph; even low concentrations of NC5 (1 uM) significantly induced apoptosis in TNBC. PBMC cells were used as a control and showed limited effects. Asterisks indicate the significance of vehicle vs. aurantiacum at the indicated concentrations. *p<0.05, **p<0.005, ***p<0.0005. Data represent mean ± SEM, n=4.
[0026] Fig.14A and 14B It was shown that NC5 inhibits proliferation by regulating the ERK pathway in TNBC; Fig.14A Results are shown after treatment of cells with NC5 (1 uM, 5 uM and 10 uM) for 24 hours. Cell proliferation was determined by MTT assay. NC5 significantly inhibited cell proliferation of MDA-231 and MDA-468 cells, but not that of PBMCs. Asterisks indicate significance of vehicle vs. aurantium tinctorium at the indicated concentrations. *p<0.05, **p<0.01, ***p<0.001. Data represent mean ± SEM, n=4; Fig. 14B The results after 24 hours of treatment of MDA-231, MDA-468 and PBMC cells with various concentrations of NC5 are shown. The protein levels of pCrkL, CrkL, cell proliferation and apoptosis-related targets were determined by Western blotting. NC5 treatment significantly inhibited pCrkL levels. β-actin was used as a loading control. The integrated density value (IDV) of the blotted bands is shown below each blot.
[0027] Fig.15 is a schematic diagram illustrating the proposed role of pCrkL in balancing proliferation inhibition and apoptosis induction in tumor or normal cells. NC5 specifically inhibits pCrkL in TNBC, which leads to inhibition of proliferation and increase in apoptosis. These events are mainly due to the regulation of downstream target proteins shown in the figure. At the same time, NC5 has little toxicity in PBMCs from healthy donors. The selective toxicity of NC5 makes it an ideal single or combination agent for chemotherapy of different solid tumor cells, with almost no side effects on normal cells.
[0028] Fig.16 is a graph showing the results obtained by flow cytometry analysis of SK-Hep1 cells pretreated with 50uM H2O2 for 1 hour to induce pCrkL activation and then incubated with 10uM NC5 or compound III for 24 hours; pCrkL (T207) expression was determined by flow cytometry. Both NC5 and compound III inhibited the pCrkL protein level induced by H2O2 in Sk-Hep1 cells.
[0029] Fig.17A and 17B It shows that NC5 has an effect on PBNK ( Fig.17A ) or CAR-NK( Fig. 17B ) Diagram of the killing effect of BXPC3.
[0030] Fig.18A and 18B It shows that NC5 and compound III can kill MDA-MB-231 ( Fig.18A ) and SK-Hep1( Fig.18B )’s effect.
[0031] Figures 19A-19E is a graph showing cell viability as a function of concentration, showing analysis of NC5, Compound III, and cytarabine ( Fig.19A ) or sorafenib ( Figures 19B-19E ) in different cell lines, including (i) human acute monocytic leukemia (AML) cell line MoLM-13 ( Fig.19A ); (ii) HepG2 cell line ( Fig.19B ); (iii) SKHep1 cell line ( Fig.19C ); (iv) Huh7 cell line ( Fig.19D ); and MDA468 cell lines ( Fig.19E ). DETAILED DESCRIPTION
[0032] Terminology Overview
[0033] The following explanations of terms and methods are provided to better describe the present disclosure, and to guide those of ordinary skill in the art to practice the present disclosure. Unless the context clearly indicates otherwise, the singular forms "a", "a kind of" and "the (said)" refer to one or more than one. Unless the context clearly indicates otherwise, the term "or" refers to a single element or a combination of two or more elements in the alternative element. As used herein, "comprising" means "including". Therefore, "comprising A or B" means "including A, B or A and B", without excluding other elements. Unless otherwise stated, all references cited herein (including patents and patent applications) are incorporated by reference as a whole.
[0034] Unless otherwise indicated, all numbers used in the specification or claims indicating the amount of a component, molecular weight, percentage, temperature, time, etc., are to be understood as being modified by the term "about". Therefore, unless otherwise indicated implicitly or explicitly, the numerical parameters are approximate values, which may depend on the desired properties sought and / or the detection limits under standard test conditions / methods. When directly and clearly distinguishing an embodiment from the prior art in question, the embodiment numbers are not approximate values unless the word "about" is explicitly stated.
[0035] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not restrictive.
[0036] The compounds herein may include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers, and tautomers thereof.
[0037] Compounds disclosed herein may contain one or more asymmetric elements, such as stereocenters, chiral axes, etc., such as asymmetric carbon atoms, so that chemical conjugates can exist in different stereoisomeric forms. These compounds may be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds may also be mixtures of diastereomers. For compounds with asymmetric centers, all optical isomers and mixtures thereof in pure form are encompassed. In these cases, single enantiomers, i.e. optically active forms, may be obtained by asymmetric synthesis, by synthesis of optically pure precursors, or by splitting racemates. The splitting of racemates may also be achieved, for example, by conventional methods, such as crystallization in the presence of a splitting agent, or chromatography using, for example, a chiral HPLC column. All forms are contemplated herein, regardless of the method used to obtain them.
[0038] Stereochemical definitions and conventions used herein generally follow those of SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., StereochemistryofOrganicCompounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of the rotation of plane polarized light by the compound, where (-) or 1 means that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory.
[0039] All forms of the disclosed compounds (eg, solvates, optical isomers, enantiomeric forms, polymorphs, free compounds and salts) may be used alone or in combination.
[0040] In any embodiment, any or all hydrogens present in a compound or in a particular group or moiety within a compound may be replaced by deuterium or tritium. Thus, the listing of alkyl includes deuterated alkyls in which from 1 to the maximum number of hydrogens present may be replaced by deuterium. For example, methyl refers to CH3 or CH3 in which from 1 to 3 hydrogens are replaced by deuterium, such as CD x H 3-x .
[0041] To facilitate review of the various embodiments of the present disclosure, the following explanations of specific terms are provided.
[0042] Administration (Administer / Administering / Administration): As used herein, administering a compound of the present disclosure or a therapeutically effective composition thereof to an individual means applying, giving, or contacting an agent with an animal by any effective route. Administration can be achieved by a variety of routes, such as parenteral administration such as intravenous administration. In some embodiments, administration can be parenteral administration, such as intravenous administration; however, other routes of administration, such as oral administration, can be utilized. The appropriate route of administration can be determined based on factors such as the individual, the condition being treated, and other factors.
[0043] Cancer: Also known as a "malignant tumor" or "malignant neoplasm," cancer refers to any of a number of diseases characterized by the uncontrolled, abnormal proliferation of cells. Cancer cells have the potential to spread locally or to other parts of the body through the bloodstream and lymphatic system (e.g., metastasis), and have any of a number of characteristic structural and / or molecular features. "Cancer cells" are cells with specific structural properties, lack of differentiation, and are capable of invasion and metastasis. Both indolent and advanced forms are included.
[0044] Contact or Exposure: Placement in direct physical association, including solid and liquid forms. In one embodiment, contact includes association between a substance or cell in a liquid medium and one or more compounds according to the present disclosure. Contact and / or exposure can occur in vitro with isolated cells or tissues, or in vivo by administration to an individual.
[0045] Pharmaceutically acceptable carriers: Remington: The Science and Practice of Pharmacy, The University of the Sciences in Philadelphia, Lippincott, Williams, & Wilkins, eds., Philadelphia, PA, 21st edition (2005) describes compositions and formulations suitable for drug delivery of one or more therapeutic compositions, such as compositions containing compound embodiments according to the present disclosure.
[0046] Generally, the character of carrier will depend on the specific mode of administration used.For example, parenteral preparations generally comprise injectable fluids, which include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solution, aqueous glucose solution, glycerol, etc. as carriers.For solid compositions (for example powder, pill, tablet or capsule form), conventional nontoxic solid carriers may include for example pharmaceutical grade mannitol, lactose, starch or magnesium stearate.Except for biologically neutral carriers, pharmaceutical compositions to be administered may contain a small amount of nontoxic auxiliary substances, such as wetting agents or emulsifiers, preservatives and pH buffers, such as sodium acetate or sorbitan monolaurate.
[0047] Pharmaceutically acceptable salts: Pharmaceutically acceptable salts of the compound embodiments described herein are derived from a variety of organic and inorganic counterions known to those of ordinary skill in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; when the molecule contains a basic functional group, salts of organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, methanesulfonate, acetate, maleate, oxalate, and the like. "Pharmaceutically acceptable acid addition salts" are a subset of "pharmaceutically acceptable salts" that retain the biological effectiveness of the free base when formed from an acid partner. In particular, the disclosed compound embodiments form salts with a variety of pharmaceutically acceptable acids, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, benzenesulfonic acid, isethionic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. "Pharmaceutically acceptable base addition salts" are a subset of "pharmaceutically acceptable salts" that are derived from inorganic bases, such as sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Exemplary salts are ammonium salts, potassium salts, sodium salts, calcium salts, and magnesium salts. Salts derived from pharmaceutically acceptable organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. (See, e.g., SM Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66: 1-19, which is incorporated herein by reference).
[0048] Prodrug: A compound embodiment disclosed herein that is most typically transformed in vivo to produce a biologically active compound, particularly a parent compound, such as by intestinal hydrolysis or enzymatic conversion. Common examples of prodrug moieties include, but are not limited to, pharmaceutically acceptable esters, carbonates, amides, and / or carbamate forms of compounds having an active form bearing a carboxylic acid moiety and / or a hydroxyl group. Examples of pharmaceutically acceptable esters of compound embodiments disclosed herein include, but are not limited to, esters of a phosphate group and a carboxylic acid, such as aliphatic esters, particularly alkyl esters (e.g., C 1-6 Other prodrug moieties include phosphate esters, such as -CH2-OP(O)(ORa )2 or a salt thereof, wherein R a is hydrogen or aliphatic (e.g. C 1-6 alkyl). Acceptable esters also include cycloalkyl esters and arylalkyl esters, such as but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compound embodiments of the present disclosure include, but are not limited to, primary amides and secondary alkyl amides and tertiary alkyl amides (e.g., having 1 to 6 carbons). Amides and esters of the disclosed exemplary embodiments of the compound embodiments of the present disclosure can be prepared according to conventional methods. A detailed discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems", Volume 14 of the ACSSymposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
[0049] Individual: A living multicellular vertebrate organism, including humans and non-human mammals (e.g., veterinary animals, including dogs and cats, as well as mice, rats, rabbits, sheep, horses, cows, and non-human primates).
[0050] Treat or inhibit a condition: "Inhibiting" a disease or condition refers to inhibiting the full development of a disease or condition such as cancer (e.g., a tumor or hematological malignancy). Inhibition of a disease or condition can cover the range of partial inhibition to substantially complete inhibition (e.g., including but not limited to prevention) of a disease or condition (such as cancer). In some embodiments, the term "inhibit" refers to reducing or delaying the onset or progression of a disease or condition. "Treatment" refers to a therapeutic intervention that improves the signs or symptoms of a disease or condition after it has begun to develop. The term "improvement" with respect to a disease or condition refers to any observable beneficial effect of treatment. The beneficial effect can be, for example, demonstrated by delayed onset of clinical symptoms of a disease or condition in susceptible individuals, a reduction in the severity of some or all clinical symptoms of a disease or condition, a slower progression of a disease or condition, an improvement in the overall health or well-being of an individual, or by other parameters known in the art that are specific to a particular disease or condition, such as improved survival of individuals with cancer. Treatment can be assessed by objective or subjective parameters; including but not limited to the results of a physical examination, imaging, or blood tests. "Preventative" treatment is treatment administered to an individual who does not show signs of a disease or condition, or who shows only early signs, with the goal of reducing the risk of developing the pathology, e.g., preventing the onset or recurrence of cancer. Individuals to whom an effective amount of a disclosed compound embodiment is to be administered can be identified by standard diagnostic techniques for such diseases or conditions, e.g., the presence of a disease or condition or risk factors for developing a disease or condition.
[0051] Therapeutically effective amount: An amount of a compound embodiment sufficient to inhibit CrkL and / or treat a particular condition or disease, or to ameliorate or eradicate one or more of its symptoms and / or prevent the occurrence of a disease or condition. The amount of a compound that constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, etc. A therapeutically effective amount can be determined by one skilled in the art with the benefit of this disclosure.
[0052] introduction
[0053] Crk family proteins, including CrkI, CrkII and CrkL, belong to the adaptor protein family and were originally discovered from the oncogene fusion product of the chicken tumor 10 (CT10) retrovirus.
[0054] CrkL and CrkII proteins contain a Src homology-2 (SH2) domain and two SH3 domains, and lack intrinsic enzymatic activity. The phosphorylation of Crk protein is one of the most important regulatory factors of its function. Specifically, the tyrosine site (Y207) in the linker region of CrkL between the two SH3 domains can be phosphorylated by kinases (such as BCR-ABL), resulting in the formation of intramolecular interactions, in which phosphorylated Y207 is combined with its SH2 domain. Intramolecular interactions reduce the possibility of pCrkL SH2 domains combining with other molecules. Therefore, phosphorylated CrkL usually plays a negative regulatory role.
[0055] Several research groups have reported that Crk family proteins are upregulated in various cancers. Specifically, Crk family proteins are upregulated in tumor cell lines and tumor tissues, such as breast cancer, lung cancer, hematopoietic cancer, glioblastoma, ovarian cancer, colon cancer, sarcoma, and melanoma, compared with corresponding benign tissues or adjacent normal tissues. Interestingly, high levels of CrkL can be used as a novel prognostic marker for hepatocellular carcinoma (HCC).
[0056] Given that elevated expression of Crk family proteins and increased pCrk have been observed in various cancers (eg, lung, breast, and ovarian), the disclosed pCrk inhibitors may have broad clinical impact.
[0057] Crk family proteins not only play an important role in cancer, but also regulate immune responses. Specifically, CrkL interacts with hematopoietic progenitor kinase 1 (HPK1) to affect interleukin-2 (IL-2) secretion in T cells. CrkII forms a complex with CbI to affect B cell antigen receptor (BCR) signaling, but does not phosphorylate CrkII. Crk plays a role in NK cell inhibitory receptor signaling and regulates the signaling of activating receptors.
[0058] Since there are many ways that Crk family proteins are involved in cancer and immune responses, blocking Crk phosphorylation or otherwise inhibiting Crk function in tumors and exhausted immune cells (e.g., CTL or NK cells with PD-1 upregulation) should not only inhibit tumor progression but also restore effective immune responses against tumors. AlphaScreen is used to identify inhibitors of phosphorylated Crk or Crk protein function, focusing on CrkL protein in this study. 71 candidate compounds from five libraries (including more than 2000 compounds) were identified using AlphaScreen as an initial screening strategy. One identified option is auranthus serratus.
[0059] The therapeutic activity of the disclosed compounds was evaluated in several in vivo tumor cancer mouse xenograft models. In certain embodiments, the disclosed compounds can inhibit tumor cell growth by inhibiting pCrk function. Mechanistic studies have found that cell growth inhibition is mainly due to increased apoptosis induced by the disclosed compound embodiments. Inhibition of pCrkL also increased the protein level of pJNK, which subsequently increased the expression of the pro-apoptotic protein BIM in tumor cells rather than PBMCs. Therefore, the therapeutic use of small molecule inhibitors of pCrk for cancer treatment is feasible.
[0060] Compound
[0061] Disclosed herein are compound embodiments that are CrkL inhibitors. In specific embodiments, the compound is selected from the compounds shown below, and any pharmaceutically acceptable salts, prodrugs, isomers or solvates thereof. In independent embodiments, the compound is not auranthus serratus (also known as "3', 4', 5-trihydroxy-6", 6"-dimethyl-6-(3-methylbut-2-ene-1-yl)-6"H-pyrano[2",3":7,8]isoflavone" or "3-(3,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-6-(3-methylbut-2-ene-1-yl)-4H,8H-(benzo[1,2-b:3,4-b']bipyran)-4-one") or a compound other than it.
[0062]
[0063] Also disclosed is the embodiment of the therapeutically effective composition, which may include one or more of the compound embodiments shown below.Such a composition embodiment may also include a pharmaceutically acceptable carrier.The disclosed therapeutically effective composition embodiment generally includes a therapeutically effective amount of the compound.In some other embodiments, based on the total weight percentage of the therapeutically effective composition, the amount of the compound ranges from greater than 0% to as high as 99% total weight percentage, for example greater than 0wt% to 95wt%, such as greater than 0wt% to 90%wt%, or greater than 0wt% to 85wt%, or greater than 0wt% to 80wt%, or greater than 0wt% to 75wt%, or greater than 0wt% to 70wt%, or greater than 0wt% to 65wt%, or greater than 0wt% to 60wt%, or greater than 0wt% to 55wt%, or greater than 0wt% to 50wt%. In some embodiments, based on the total weight percentage of the therapeutically effective composition, the therapeutically effective composition of the compound disclosed herein can include greater than 0wt% to 95wt%, such as 0.001wt% to 95wt%, or 0.01wt% to 95wt%, or 0.1wt% to 95wt%, or 1wt% to 95wt%, or 5wt% to 95wt%, or 10wt% to 95wt%, or 25wt% to 95wt% of the compound. In some embodiments, any remaining weight percentage of the composition can be made up by a pharmaceutically acceptable carrier.
[0064] Compounds disclosed herein (or any therapeutically effective composition thereof) can be applied in the form of solid, liquid and / or lotion. Suitable solid application forms include, but are not limited to, tablets, capsules, powders, solid dispersions, etc. containing compounds disclosed herein (or any therapeutically effective composition thereof). Suitable liquid or lotion forms include, but are not limited to, oil-in-water or water-in-oil emulsions, hydrogel compositions, or liquids or lotions containing compounds disclosed herein (or any therapeutically effective composition thereof), which are formulated as foams, membranes, sprays, ointments, vaginal suppositories (pessary form), suppositories, creams, liposomes, or other forms embedded in a matrix for use, for sustained release or controlled release of compounds disclosed herein (or any therapeutically effective composition thereof) to skin or surfaces to which it has been applied or in contact. In specific disclosed embodiments, skin patches can be used to promote administration and delivery of compounds disclosed herein (or any therapeutically effective composition thereof). In other embodiments, compounds disclosed herein (or any therapeutically effective composition thereof) can be formulated as gels for topical application.
[0065] The compounds disclosed herein (or any therapeutically effective composition thereof) can be formulated for a variety of modes of administration, including, but not limited to, topical, ocular, oral, buccal, systemic, nasal, injection (such as intravenous, intraperitoneal, subcutaneous, intramuscular or intrathecal), transdermal (e.g., by mixing with a penetrant such as DMSO), rectal, vaginal, in a form suitable for administration by inhalation or insufflation, in a form suitable for implantation, or any combination thereof.
[0066] For oral or buccal administration, the compounds disclosed herein (or any therapeutically effective composition thereof) can be in the form of lozenges, tablets, or capsules, prepared using conventional means with pharmaceutically acceptable excipients, which will be recognized by those skilled in the art with the benefit of this disclosure. Tablets or capsules can be coated with, for example, sugar, film, or delayed release, sustained release, and / or enteric coatings by methods well known in the art.
[0067] Liquid preparations of compounds disclosed herein (or any therapeutically effective compositions thereof) for oral administration can take the form of, for example, elixirs, solutions, syrups or suspensions, or they can be presented as dry products constructed with water or other suitable solvents before use. Preparations for oral administration can also be suitably formulated to provide controlled release of compounds or compositions.
[0068] For topical administration, the compounds disclosed herein (or any therapeutically effective composition thereof) may be formulated as solutions, lotions, gels, ointments, creams, suspensions, etc. For transmucosal administration, penetrants appropriate to the barrier to be permeated may be used.
[0069] Systemic formulations include those designed for administration by injection (e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection), as well as those designed for transdermal, transmucosal, oral or pulmonary administration. Useful injectable formulations include sterile suspensions, solutions or emulsions of the compounds disclosed herein (or any therapeutically effective composition thereof) in aqueous or oily vehicles. The composition may also contain a preparaton, such as a suspending agent, a stabilizer and / or a dispersant.
[0070] For rectal routes of administration, the compounds disclosed herein (or any therapeutically effective composition thereof) can be formulated as solutions (for retention enemas), suppositories, or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
[0071] For nasal administration or administration by inhalation or insufflation, the compounds disclosed herein (or any therapeutically effective composition thereof) can be conveniently delivered in the form of an aerosol spray from a pressurized pack or nebulizer using a suitable propellant. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges for use in an inhaler or insufflator (e.g., capsules and cartridges composed of gelatin) can be formulated as a powder mix containing a compound disclosed herein (or any therapeutically effective composition thereof) and a suitable powder base such as lactose or starch.
[0072] In some embodiments, the above-mentioned compound IV can be prepared by treating auranthus serratus with a rhenium (VII) oxide catalyst to promote the dehydration condensation reaction between phosphoric acid and the 1,2-diol group of auranthus serratus. In other embodiments, bis (dimethylamino) diaminophosphoric acid ester can be used to promote this conversion to obtain compound IV. In some embodiments, compound V can be prepared by exposing auranthus serratus to a suitable oxidant to oxidize the 1,2-diol group to the corresponding oxo group, as shown in compound V. In some embodiments, compound II can be prepared by exposing auranthus serratus to a base (e.g., Et3N) and sulfonyl fluoride (SO2F2) in tetrahydrofuran (THF) in the presence of 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or exposing auranthus serratus to 4-[(acetylamino) phenyl] imino disulfonyl difluoride reagent (AISF). In other embodiments, the 1,2-diol of compound I-III can be protected by reacting aurantium or a sulfonyl fluoride intermediate with SO2F2, as shown in Scheme 1 below.
[0073]
[0074] Route 1
[0075] method
[0076] A new treatment strategy is disclosed herein that can not only directly inhibit cancer cell proliferation, but also restore exhausted immune cell function. This treatment strategy can be developed by targeting pCrkL, which is a common main signaling molecule triggered by multiple inhibitory receptors such as NKG2A and PD-1. In a specific embodiment, a method of using a compound according to the present disclosure is described, wherein the method includes exposing a sample or an individual to a compound of the present disclosure or a therapeutically effective composition thereof. In some embodiments, the method is a method of inhibiting Crk-mediated signaling pathways or a method of enhancing immune cell responses in an individual suffering from or suspected of suffering from chronic viral infection or cancer. In a specific embodiment, the compound is one of the compounds IV disclosed herein, wherein a representative embodiment uses compound III. In a specific embodiment, compared with orange mulberry flavonoids, compound III shows better performance in the method embodiments disclosed herein.
[0077] Phosphorylated CrkL (pCrkL) inhibitors can be used to enhance immune cell responses in chronic viral infections and cancers. Data demonstrating phosphorylation-driven conformational changes in CrkL and pCrkL inhibitor compounds disclosed herein are disclosed herein. These newly identified pCrkL inhibitors have the potential to significantly change the face of cancer treatment and infectious disease (e.g., chronic HIV infection) treatment by preventing the downregulation of immune responses to cancer and infectious diseases while directly inhibiting cancer cells or infected cells. Unlike efforts to enhance T cell responses using antibodies targeting single inhibitory receptors (e.g., PD-1, CTLA-4, LAG-3, and CD160), the proposed strategy is to first address the common downstream central signaling center CrkL of several inhibitory receptors in immune cells and the cell proliferation of cancer cells. In addition, since other chronic viral infections are accompanied by increased expression of inhibitory receptors, and increased expression and increased phosphorylation of Crk family proteins are observed in a variety of cancers (e.g., lung, breast, and ovary), pCrk inhibitors may have a wide range of clinical impacts.
[0078] Although SHP-2 is one of the well-recognized downstream signaling molecules of PD-1 signaling, no specific SHP-2 inhibitors are clinically available despite three decades of efforts. The data presented here suggest that Crk functions as a molecular switch that controls cytotoxic lymphocyte activation by switching between phosphorylated and non-phosphorylated states. Phosphorylation of Crk can be induced by different inhibitory receptors such as CD94 / NKG2A, KIR2DL1 and KIR2DL2 (manuscript in preparation) and PD-1 (manuscript in preparation) in different types of cytotoxic lymphocytes, including NK cells and CTLs. Therefore, pCrk is a valid therapeutic target.
[0079] Existing chemical libraries, both proprietary and public, contain thousands of compounds, many of which have been used for excellent therapeutic purposes. One such example is Gleevec, an inhibitor of Abl kinase used to treat leukemia. However, Gleevec cannot be used to restore exhausted immune cells because, in addition to phosphorylating Crk, Abl is also required for T cell activation. In addition, typical drug screening methods for small molecule inhibitors are expensive and time consuming, and some, such as 32 The pCrkL assay has significant safety implications. Herein, a unique combination of high-throughput AlphaScreen, kinase and thermal drift assays, and smFRET technology was used to identify and characterize multiple pCrkL inhibitors. Restoring exhausted immune cell function to control tumor growth and infection using pCrk inhibitors represents a conceptual and technical innovation in cancer immunotherapy by simultaneously restoring exhausted immune cell function and inhibiting tumor growth.
[0080] Recently, CrkL is emerging as an important player in cancer and immune response. The phosphorylation state of CrkL is highly regulated under different conditions. In cancers such as acute lymphoblastic leukemia, phosphorylated CrkL or CrkII can be used as a biomarker to monitor the assessment of BCR-ABL activity in patients. In the human immune system, for example in NK cells, CrkL acts as a molecular switch based on its phosphorylation state. CrkL has oncogenic potential and is overexpressed in many cancers, which is associated with the malignant state of cancer. On the other hand, CrkL also plays a very important role in the immune response.
[0081] Since this important role of CrkL in human cancer and the immune system has been demonstrated, there is a need in the art for drugs that can specifically block CrkL function. In theory, inhibition of phosphorylated CrkL leads to dysfunctional cancer cells and enhances immune cell function. Based on this cognition, potential drugs that inhibit CrkL phosphorylation will be bifunctional. Unfortunately, in addition to siRNA or miRNA targeting CrkL expression at the transcriptional level, there are no reports of drugs that inhibit CrkL or phosphorylated CrkL in previous studies. As disclosed herein, new drugs are discovered using AlphaScreen technology based on the in vitro kinase activity of Abl to CrkL protein. Alpha signals can detect this kinase activity, which can also be blocked by drug-mediated interruption of the interaction between Abl and CrkL. Five libraries (a total of 2312 drugs) were screened, and 71 drugs were found to be positive. Thermal drift was also performed to confirm the interaction between the protein (Abl or CrkL) and the candidate drug, and 5 drugs were found to bind to Abl and 5 drugs to CrkL. The effect of the candidate drug on CrkL phosphorylation was then confirmed by two methods: in vitro kinase assay and single molecule FRET. After in vitro confirmation, functional assays were performed in cancer cells and immune cells. Auricularia serrata (also referred to herein as "NC5") inhibits breast cancer cell proliferation but not immune cell function. In two different xenograft animal models established using the MDA-MB-231 cell line and TNBC patient tumors, auricularia serrata can effectively inhibit TNBC tumor growth. No physiological appearance changes, liver or kidney toxicity were detected during auricularia serrata treatment, thus indicating the preclinical safety of the drug. These data suggest that auricularia serrata treatment may be a promising anticancer drug, used alone or in combination with other drugs clinically.
[0082] It has been reported that overexpression of CrkL occurs in various tumor cells. Although the importance of CrkL and phosphorylated CrkL has been reported since the discovery of this oncoprotein, there is no known specific drug that can inhibit its function. In previous studies, CrkL was found to be phosphorylated by BCR-ABL in chronic myeloid leukemia, and phosphorylated CrkL was found to act as a monitor of ABL kinase activity. Therefore, in most studies, drugs are screened for targeting Abl activity. Few studies focus on how to inhibit CrkL phosphorylation. Although Gleevec is an excellent inhibitor of Abl kinase, which directly phosphorylates Crk protein, Gleevec cannot be used to restore exhausted immune cell function because, in addition to phosphorylated Crk, Abl is also required for T cell activation. This study identified a specific CrkL inhibitor that can be used as a potential treatment for other cancers.
[0083] Based on the role of CrkL in cancer and immune cells, candidate compounds that not only inhibit cancer cell function but also restore exhausted immune cell function are screened. Highly specific aurantium serrata inhibits the proliferation of several solid tumor cells, such as breast cancer, HCC, and PDAC cells, but does not affect immune cell function. Aurantium serrata also specifically affects several CrkL-related signaling pathways, which regulate cell proliferation and apoptosis of TNBC and HCC, but has limited effects in immune cells. Therefore, one advantage of aurantium serrata is that it does inhibit the growth of solid cancer cells in vivo without affecting immune cell function. The compound embodiments disclosed herein, including compound IV, exhibit excellent inhibitory effects relative to aurantium serrata. Therefore, these compounds can be used in the method embodiments disclosed herein.
[0084] Overview of several implementation plans
[0085] Disclosed herein are compounds selected from the group consisting of:
[0086]
[0087] Also disclosed herein are embodiments of therapeutically effective compositions comprising a compound according to any one of the above compounds and a pharmaceutically acceptable carrier.
[0088] In any or all of the above embodiments, the compound is formulated to inhibit or prevent tumor cell growth without inhibiting immune cell function.
[0089] Also disclosed herein are embodiments of methods of inhibiting a Crk-mediated signaling pathway comprising exposing a sample or an individual to a compound according to any or all of the above embodiments, or a therapeutically effective composition thereof.
[0090] In any or all of the above embodiments, the sample is an in vitro or ex vivo sample.
[0091] In any or all of the above embodiments, the compound inhibits proliferation of tumor cell lines but does not inhibit immune cell function.
[0092] Also disclosed herein are embodiments of methods of enhancing immune cell responses in an individual suffering from or suspected of suffering from a chronic viral infection or cancer, comprising administering to the individual a compound according to any or all of the above embodiments, or a therapeutically effective composition thereof.
[0093] Example
[0094] Example 1
[0095] In this example, compounds III and I were synthesized as described herein. TEA (0.41 mL, 2.97 mmol, 5 eq) was added to a mixture of aurantiacum and Aurisculasin (1:1) (250 mg, 0.59 mmol) in THF (25 mL). After cooling to -78°C, a stream of sulfonyl difluoride was bubbled through the solution for 20 seconds. The reaction was allowed to warm to room temperature and stirred for two days. The solvent was removed under reduced pressure. FCC (20% EtOAc / Hex) provided two samples: Compound III (107 mg) as a yellow solid; and Compound I as a colorless foam (98 mg).
[0096] Example 2
[0097] Drugs and sources of compound libraries: NC5 (also known as aurantium flavonoids) was purchased from MicroSource Discoverysystems, Inc (Gaylordsville, CT). Five compound libraries of potential inhibitors of phosphorylation at Y207 of CrkL were obtained from several sources, including Enzo Screen-Well Kinase Inhibitors (number of compounds = 80), EnzoScreen-Well Phosphatase Inhibitors (number of compounds = 33), MicroSource Natural Products (number of compounds = 800), NCI Natural Product Set II (number of compounds = 119), and SigmaLOPAC (number of compounds = 1280). Most of the compound libraries were provided by the Center for Drug Discovery at Baylor College of Medicine. Some of the compound libraries were purchased from MicroSource Discovery Inc.
[0098] Cell culture: in R10 medium (RPMI medium 1640, Corning TM ), 10% fetal bovine serum (FBS), 100 U / mL penicillin-streptomycin (Corning TM ), 2 mM L-glutamine (Corning TM Human peripheral blood mononuclear cells (PBMCs) isolated from healthy donors were cultured in 5% paraformaldehyde (20 mM) and 20 mM HEPES (Sigma) and adjusted to pH 7.0. TMBreast cancer cell lines were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (10% FBS and 100 U / mL penicillin-streptomycin). HCC cell lines used in this example, including HepG2 and Sk-Hep1 cells, were cultured in DMEM containing 10% FBS. PDAC cell lines such as BXPC3 cells were cultured in R10 medium.
[0099] Antibodies and reagents: For the AlphaScreen assay, nickel chelate donor beads attached to 6x histidine-tagged CrkL and anti-rabbit IgG acceptor beads attached to Tyr207 antibody were purchased from PerkinElmer. Antibodies for western blotting were purchased from Cell Signaling Technologies (Danvers, MA) and included the following: pCrkL (Tyr207, #3181), pErk1 / 2 (Thr202 / Tyr204, #4370), pJNK1 / 2 (Thr183 / Tyr185, #9255), ERK1 / 2 (#9102), JNK1 / 2 (#9252), Bim (#2819), and HRP-linked anti-rabbit antibody (#7074). CrkL antibody (C-20) was purchased from Santa Cruz Biotechnology. β-actin antibody was obtained from Millipore-Sigma (St. Louis, MO). For thermal drift assays, Orange protein gel stain was purchased from Life technology. For proliferation assay, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) cell proliferation assay kit was purchased from Cayman Chemical. For IL-2 ELISA assay, human IL-2 ELISA kit was purchased from Ray Biotech.
[0100] Cell transfection and infection: Initially, CrkL cDNA was ligated into the overexpression plasmid vector pCMV6-XL4, which was purchased from OriGene Technologies (Rockville, MD, USA). HEK293T and K562 cells were then transfected with CrkL (and GFP control plasmid) plasmids using Amaxa Nucleofection technology according to the manufacturer's protocol. Briefly, HEK 293T and K562 cells were transfected with Solution V.Cells and mixed with plasmid DNA in Nucleofector Solution V. The cells were then transferred to a cuvette and the appropriate Nucleofector program was used. For example, Q-001 and T-016 programs were used for HEK293T and K562 cell transfections, respectively.
[0101] Amplified chemiluminescent affinity homogeneous detection (AlphaScreen): The AlphaScreen assay is designed to detect conformational changes due to protein-protein interactions as well as protein phosphorylation. Compounds were screened from each of the five libraries described above using this assay to identify the most potent inhibitors of phosphorylation at Y207 of CrkL. Briefly, 0.5 μg / ml Abl was mixed in a 15 μl volume in the presence of 0.5 μg / ml CrkL, 10 μm ATP, and 0.2 mg / ml pCrkL. All reagents were diluted in kinase buffer (1 mM DTT, 0.2% w / v BSA, 100 mM Nalco, 0.01% w / v Tween-20, 1.0 mM MgCl2, 20 mM Tris, adjusted to pH 7.4). Then, 0.1 μl of 10 mg / ml Gleevec (imatinib mesylate, also used as a control at the same concentration as the test compound) was added and incubated for 2 hours at room temperature (RT). After incubation, 5.0 μl of 20 μg / ml acceptor beads linked to pTyr207 antibody was added and incubated for 1 hour at RT. After incubation with the acceptor beads, 5.0 μl of 20 μg / ml nickel chelate donor beads attached to 6× histidine-tagged CrkL were added and incubated for 1 hour at RT. The signal of the AlphaScreen assay was measured by an Infinite M1000 Pro microplate reader (Tecan, Switzerland).
[0102] Thermal drift assay: The thermal drift assay is a thermal denaturation assay that measures the thermal stability of the protein being tested. When the protein of interest binds to the ligand (or drug), its melting temperature increases. For each single-well assay, CrkL (1 μg / well), Orange (1:500 stock dilution), candidate drug (final concentration same as in AlphaScreen) and reaction buffer (1×TBS) were mixed. The total volume per well was 10 ul. The assay was quantified by melting curve on a real-time PCR machine using a melting temperature ranging from 20°C to 95°C.
[0103] In vitro kinase assay: In vitro kinase assay was performed to detect phosphorylation of CrkL by Abl and to determine whether candidate drugs identified in AlphaScreen assay can inhibit phosphorylation. In a 20 μl reaction system, the following were mixed: 2.5 μg CrkL protein, 0.04 μg Abl protein, 40 μM candidate drug (same concentration as in AlphaScreen assay), and kinase buffer (1 mM DTT, 0.2% w / v BSA, 100 mM Nalco, 0.01% w / v Tween-20, 1.0 mM MgCl2, 20 mM Tris, adjusted to pH 7.4) containing ATP (Cell Signaling Technology, MA, USA) was added to 20 μl. To compare specific in vitro kinase activity, two different reactions (one with Abl protein and one without Abl protein) were prepared. After mixing the above kinase buffer (without Abl) at 30°C for 30 minutes, Abl kinase was added and incubated at 30°C for 1 hour. Western blot loading buffer and DTT were added to all samples and they were denatured in 100°C water for 30 minutes. Total CrkL expression was detected using C20 antibody, which was used as an internal control in this assay. pTyr207 antibody detected the level of phosphorylated CrkL. Gleevec was used as a positive control in this kinase assay.
[0104] Single molecule fluorescence resonance energy transfer (smFRET): Single molecule fluorescence resonance energy transfer (smFRET) is used to monitor the conformation of single molecules. CrkL has two cysteines (relatively rare amino acids), one in its SH2 and the other in the SH3C domain. CrkL was mixed with an equal amount of a mixture of Alexa555-maleimide and Alexa647-maleimide (Invitrogen, USA) (10 times higher than the protein concentration) to randomly label the two cysteines. The labeled protein was purified from the unreacted dye by gel filtration. Molecules with only one donor and acceptor were identified in the single molecule data analysis and used for further analysis. The labeling efficiency was 50-100% as assessed by UV-VIS absorption spectroscopy. The FRET change between unphosphorylated CrkL and phosphorylated CrkL was measured. The dye-labeled proteins were used in in vitro kinase assays with different drug treatments as described above. sMFRET measurements were performed using prism-based total internal reflection microscopy (TIRF), where the FRET efficiency was determined by measuring the donor and acceptor intensities (I d and I a ) by FRET = I a / (I d +I a ) as described previously. To surface immobilize 6xHis-tagged CrkL, the protein was added to a biotinylated 6xHis antibody (Thermo Scientific Cat. No. MA1-80087) conjugated to streptavidin adsorbed on a quartz slide. The quartz surface was passivated using a lipid bilayer. Immobilized Crk was phosphorylated in situ.
[0105] MTT assay: Cell proliferation was detected using the MTT assay. Briefly, cells were plated at a density of 50,000 cells / well in 200 μl of culture medium containing the candidate drug to be tested (DMSO as a negative control) in a 96-well plate. The treated cells were incubated in a 37°C, 5% CO2 incubator for 4 hours to allow dark crystals to form at the bottom of the wells. After 48 hours of incubation, 10 ml of MTT reagent was added to each well and gently mixed for 1 minute. After aspirating the culture medium from each well, 100 μl of crystal dissolution solution was added to each well and incubated at RT for 10 minutes. The signal was quantified by measuring the absorbance of each sample at 570 nm using a microplate reader.
[0106] IL-2 ELISA: Human IL-2 production was measured using an IL-2 in vitro enzyme-linked immunosorbent assay (ELISA). The assay was performed according to the user manual of the kit. Briefly, human PBMCs were cultured in R10 medium containing 0.5 μg / ml PHA. Then, 100 μl of standards and samples were added to each well and incubated overnight at 4°C. Prepared biotin antibody (100 μl) was added to each well and incubated at room temperature for 1 hour. Then, 100 μl of prepared streptavidin solution was added and incubated at room temperature for 45 minutes. TMB one-step substrate reagent (100 μl) was then added to each well and incubated at room temperature for 30 minutes. Stop solution (50 μl) was then added to each well, and the results were immediately quantified at 450 nm by an Infinite M1000 Pro microplate reader (Tecan, Switzerland).
[0107] Annexin V / PI staining: Experimental cells were collected, washed with 1xPBS, resuspended in binding buffer, and stained with the Annexin V-FITC assay kit (Millipore Sigma). Cells were incubated with 50 μg / ml Annexin V in 1x binding buffer for 15 minutes at room temperature, then incubated with 10 μg / ml propidium iodide for another 15 minutes and analyzed by flow cytometry (EPICS XL). Annexin V positive / PI negative cells were considered early apoptotic, cells positive for both Annexin V and PI were late apoptotic, and cells negative for Annexin V but positive for PI were "necrotic". The percentage of apoptosis was calculated as the sum of the percentage of early apoptotic cells and late apoptotic cells.
[0108] Western blot: According to the company's protocol (Thermo Scientific, Waltham, MA). Western blots were performed using 20ug of total cell extracts. Briefly, the transferred membranes were incubated with the primary antibody for 1 hour overnight, followed by incubation with the HRP-linked secondary antibody for 1 hour, depending on the sensitivity of each antibody. Each membrane was stripped and reprobed for b-actin, which served as an internal loading control. Protein bands were visualized using a chemiluminescent detection system (Thermo Scientific). The relative optical density of each band was quantified and indicated by a number below the band in each western blot.
[0109] Xenograft studies: Breast cancer cell line-derived xenograft models and patient-derived xenografts (PDX) were used in this evaluation. The mouse xenograft protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Animals were maintained and evaluated under pathogen-free conditions in accordance with IACUC guidelines.
[0110] To establish a breast cancer cell line xenograft model, female NSG mice (8 weeks old) were used. Specifically, these NSG mice were injected subcutaneously with 1×10 6 Briefly, MDA-MB-231-GFP-LUC tumor cells were cultured, detached with 0.25% trypsin to produce a single-cell suspension, and incubated with Matrigel TM (Corning TM ) were mixed. For each mouse, 1×10 6 Tumor cells were injected into the fourth mammary fat pad.
[0111] For HCC or PDAC xenograft models, NSG mice (8 weeks old) were subcutaneously injected with 1×10 6 HepG2 or BXPC3 tumor cells.
[0112] By dividing 5×10 4 4T1-Luc cells mixed with Matrigel were inoculated into the left inguinal fat pad of Balb / c mice from Jackson Laboratory to establish a mouse model bearing syngeneic orthotopic 4T1 breast tumors. This orthotopic syngeneic breast tumor model is a tool for preclinical testing of anticancer drugs or immunotherapies, which require an intact immune system to elicit activity.
[0113] For patient-derived xenograft (PDX) models, a panel of mice implanted with TNBC tumor model #TM00089-breast tumor markers: TNBC ER-(estrogen receptor negative) / PR-(progesterone receptor negative) / HER2-(human epidermal growth factor receptor 2 negative), BRCA1 V757fs (4- to 6-week-old females) were obtained from Jackson Laboratory (Bar Harbor, ME). TM PDX models were generated in the mammary fat pad of non-obese diabetic, severe combined immunodeficient, interleukin-2 receptor γ chain-deficient) mice.
[0114] In all tumor models, tumor growth was recorded twice weekly by caliper measurement and volume was calculated using the formula (length 'width' width) / 2. One week after tumor injection, or three days after receiving TNBC PDX mice from Jackson Laboratory, the mice were administered with vehicle (0.5% Mice were treated once daily with Avicel (0.5% Avicel), Gleevec (imatinib mesylate, 40 μg / g) or Aurora mulberry flavonoids (5 μg / g). For HCC or PDAC xenograft models, mice were treated with vehicle (0.5% Avicel), Aurora mulberry flavonoids (5 ug / g) and Compounds I, II or III (5 ug / g). For orthotopic syngeneic breast tumor models, inoculated mice were treated with vehicle (0.5% Avicel), Aurora mulberry flavonoids (5 ug / g) or Compound III (5 ug / g). When the tumor size reached 2 cm in diameter in a single dimension, mice were sacrificed according to IACUC guidelines. Tumor material was collected for protein analysis by rapid freezing in liquid nitrogen and histological studies by formalin fixation.
[0115] Mouse toxicity assay: Blood was collected from the submandibular vein before and 20 days after drug treatment in accordance with IACUC guidelines (CMP, Houston Methodist Research Institute and Rutgers University). Clinical biochemistry and pharmacokinetic tests were performed by the Department of Veterinary Medicine & Surgery at MD Anderson Cancer Center. Serum chemistry analysis included alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine level measurements.
[0116] Statistical analysis: Each experiment was performed at least three times. The results are expressed as mean ± standard error (SE). The significance of differences between means was assessed by two-tailed Student's t-test or ANOVA using GraphPad Prism 8.0 software (Graph-Pad Software; San Diego, CA). p < 0.05 was considered statistically significant.
[0117] To identify specific compounds that inhibit Y207 phosphorylation of CrkL, the AlphaScreen assay was designed to screen five compound libraries of potential inhibitors from the Center for Drug Discovery at Baylor College of Medicine (BCM). Nickel chelate donor beads were linked to hexa-histidine-tagged CrkL (6xHis-CrkL). When 6xHis-CrkL is phosphorylated at Y207 by Abl kinase, 6xHis-pCrkL can be detected by a specific anti-pCrkL antibody Tyr207 (rabbit IgG) that has been linked to an acceptor bead ( Figure 1A When 6xHis-pCrkL binds to the donor beads labeled with the Tyr207 antibody, the distance between the acceptor beads and the donor beads becomes close enough to generate a signal detected by the microplate reader ( Figure 1A ).
[0118] Specifically, when excited at 680nm, the donor beads (nickel-chelated donor beads that can be conjugated to 6xHis-CrkL fusion protein) produce singlet oxygen molecules. If the acceptor beads (anti-rabbit IgG coated acceptor beads) are within 200nm of the donor beads, the singlet oxygen transfers energy to the donor beads, resulting in the generation of 520 to 620nm light. The amount of light generated is proportional to the amount of bound donor-acceptor beads. When a potential pCrkL inhibitor candidate is added to the reaction, the specific pCrkL inhibitor can directly bind to the CrkL phosphorylation site (Tyr207), inhibiting the interaction between CrkL and Abl, resulting in a reduced or absent CrkL phosphorylation signal. Using AlphaScreen technology, 2312 drugs were screened and classified into five libraries ( Figure 1B ): Phosphatase inhibitors (number of compounds = 33), Kinase inhibitors (number of compounds = 80), NCI Natural Products (number of compounds = 119), Natural compounds (number of compounds = 800), and Sigma LOPAC (number of compounds = 1280).
[0119] To quantify the AlphaScreen data, the detection signals (generating light between 520 nm and 620 nm) from all screened compounds were normalized to the dot plot. Each compound was replicated and plotted on the x- and y-axes ( Figure 1B ).
[0120] Positive selection was defined as a 50% reduction in Alpha signal compared to the negative control (DMSO treatment). Gleevec (STI-571) is a highly successful anticancer drug that inhibits Abl, an upstream kinase of Crk. Gleevec was used as a positive control for this AlphaScreen assay. In the Gleevec treatment group (positive control), a reduction in Alpha signal of more than 80-90% ( Figure 1B ).
[0121] To further validate the AlphaScreen assay, a different pY207 antibody was used to detect the Alpha signal. A dose-dependent increase in the Alpha signal was observed in this AlphaScreen assay ( Figure 1C ). Thus, the data demonstrate that anti-pCrkL antibodies (indicated by the symbol ■) increase bead interaction in a concentration-dependent manner.
[0122] Using this technique, eight compounds (from the natural compound [NC] library) that inhibit Crk phosphorylation were identified ( Figure 1D ); therefore, it was concluded that the AlphaScreen design was efficient and successful in the assay.
[0123] In the initial AlphaScreen assay, Gleevec was used as a positive control. Inhibitors identified via the AlphaScreen assay will either: 1) inhibit Abl function (such as Gleevec) or 2) block access to Tyr207 by preventing phosphorylation, thereby reducing the CrkL phosphorylation signal. The latter could theoretically occur through binding of small molecule inhibitors to Abl or Crk; therefore, different assays were designed to distinguish between these two possibilities.
[0124] To identify specific pCrk inhibitors, thermal shift and in vitro kinase assays were used to distinguish between these possibilities. In the thermal shift assay, each test protein (purified Abl or CrkL) has a melting temperature (T m ), which is detected by protein staining dyes such as Sypro Orange. After binding to the drug, the protein is tested for T m will increase because higher temperatures are required to unfold the protein ( Figure 2A A total of 71 candidate compounds from different libraries, previously identified by initial AlphaScreen assays, were evaluated on CrkL and Abl. m An increase of 2°C or greater (steady increase in three independent experiments) was defined as a positive result in these thermal shift assays.
[0125] like Figure 2B As shown, the T of CrkL mWhen NC5 was added to the reaction, five drugs (two from the natural compound library and three from the NCI natural product library) were found to enhance protein T binding in CrkL. m ( Figure 2C Regarding Abl kinase binding (as a control), five drugs (all from a kinase inhibitor library) were found to significantly increase T in the thermal drift assay. m ( Figure 2D Compared with the positive control Gleevec, the two compounds K5 and K8 showed similar T m Increase (T m The results showed that the NC5 from the natural compound library and C1 from the NCI natural product library share the same chemical name; NC6 (natural compound) is an isoform of C8 (NCI natural product). Based on the selection platform, no single compound can bind to both Abl and CrkL proteins; therefore, NC5 is a promising candidate that specifically binds to Crk but not Abl proteins.
[0126] To further validate pCrkL inhibitors, a kinase assay was designed to evaluate the specificity of the positive options. The in vitro kinase assay is a practical method to validate the effect of candidate compounds on CrkL phosphorylation. In this assay, CrkL protein can be phosphorylated by Abl kinase at 30°C in the presence of ATP. When a drug (e.g., Gleevec) is added to the reaction, the interaction between Abl and CrkL is blocked, thereby reducing the amount of phosphorylated CrkL. The reduction in pCrkL can be detected and quantified by this kinase assay. Here, an improved kinase assay is used to confirm that the candidate molecule does inhibit CrkL phosphorylation. Figure 3A Representative Western blots are shown. Note that NC5 inhibits Abl phosphorylation at the 37 kD CrkL band.
[0127] A total of 10 drug candidates (5 binding to Abl and 5 binding to CrkL) were validated by in vitro kinase inhibition assays followed by thermal shift analysis. Figure 3A and 3B As shown, after in vitro kinase assay, CrkL and phosphorylated CrkL were detected by Western blot analysis. For total CrkL detection, antibody C20 was used in this experiment to detect phosphorylated CrkL, which is a band shift of non-phosphorylated CrkL ( Figure 3A , shown at higher molecular weight). For phosphorylated CrkL detection, only phosphorylation at Tyr207 was specifically detected by the anti-phospho-CrkL antibody ( Figure 3B ).exist Figure 3BIn the results, different band signals of pCrkL were observed after the drugs bound to CrkL protein, indicating that these candidate drugs have different abilities to bind and inhibit CrkL phosphorylation. Compared with Gleevec (positive control), drugs that bind to Abl (such as K5, K6, K7 and K8) and drugs that bind to CrkL (NC5 and C12) showed comparable results similar to the kinase inhibition observed with Gleevec. Based on the results of AlphaScreen assay, thermal drift assay and in vitro kinase assay (results are shown in Figure 3C NC5 was selected for further study.
[0128] In intramolecular smFRET, nonradiative energy transfer occurs when two fluorophores attached to different parts of a molecule move closer together. Previous studies have shown that pCrk exists in a closed molecular conformation, while non-phosphorylated Crk exists in an open conformation, which allows smFRET changes to report phosphorylation status (see Figure 4A and 4B ). CrkL and the mutant (non-phosphorylatable) CrkL-Y207F were labeled using cysteine-maleimide based chemistry. CrkL has cysteine (a relatively rare amino acid) in its SH2 (labeled with AlexaFluor555) and SH3C (labeled with AlexaFluor647). When CrkL is phosphorylated, FRET is high ( Figure 4D , line labeled "CrkL+Abl"); when dephosphorylated, FRET decreased (Figure 4, line labeled "CrkL+Abl+Gleevec"); (and these are consistent with the "open" and "closed" states described above). Mutation of CrkL to a non-phosphorylated form (Y207F) prevented the transition to an open molecular conformation (data not shown). Similarly, specific inhibitors of Crk phosphorylation are expected to result in a decrease in the FRET ratio ( Figure 4C ).like Figure 4C As shown in the smFRET histogram, in Mg 2+ Addition of Abl to increase pCrkL in the presence of Mg and ATP resulted in higher FRET, which was inhibited by Gleevec or NC5 (55%). The CrkL-Y207F mutant showed no shift in smFRET (data not shown). Western blotting (WB) and immunoprecipitation (IP) were used to verify that the tagged protein retained the same overall functional properties as wild-type CrkL (e.g., being phosphorylatable and able to bind SH2 and SH3 ligands). In brief, in the presence of Mg 2+ Site-specifically labeled CrkL was mixed with Abl in the presence of 5% and ATP. A single AlphaScreen-identified candidate inhibitor was then added to each assay. Inhibition of Crk phosphorylation resulted in a decrease in FRET in a concentration-dependent manner.
[0129] To confirm that NC5 can inhibit CrkL phosphorylation, the smFRET assay was applied to detect conformational changes caused by protein phosphorylation after drug binding. Figure 4D As shown, when Abl protein is added, the FRET signal of CrkL changes from the non-phosphorylated state (the red line marked "CrkL", about 0.4) to the phosphorylated state (the line marked "CrkL+Abl", about 0.6). Adding Gleevec to the reaction inhibits CrkL phosphorylation and shifts the FRET signal back to 0.4 ( Figure 4D , line labeled "CrkL+Abl+Gleevec"). Therefore, Gleevec was used as a positive control. The effect of NC5 on the conformational change of phosphorylated CrkL was examined. The data showed that NC5 can also shift the FRET signal back to a lower state of CrkL (from 0.6 to 0.5) by blocking phosphorylation ( Figure 4D , black line). In summary, it was found that NC5 directly binds to CrkL protein and inhibits CrkL phosphorylation in vitro. Therefore, compound IV is also considered to exhibit similar binding behavior.
[0130] Next, the in vivo function of aurantia serrata was further evaluated by using a cell-based system. Given that CrkL is overexpressed in breast cancer, the effects of aurantia serrata on three breast cancer cell lines were evaluated: MDA-MB-231, MDA-MB-468, and Hs578T. The three breast cancer cell lines were treated with 2.5 μM Gleevec (control group), 2.5 μM aurantia serrata, and 1:4000 diluted DMSO (vehicle group). In the Hs578T cell group, both Gleevec (p < 0.05) and aurantia serrata (p < 0.01) had an inhibitory effect on proliferation, but no significant difference was observed between Gleevec and aurantia serrata ( Figure 5A , upper left figure). In the MDA-MB-231 cell group, only aurantium flavone treatment blocked cell proliferation (p < 0.05), while Gleevec had no effect on MDA-MB-231 cell proliferation ( Figure 5A , middle left figure). In the MDA-MB-468 cell group, similar results were obtained in cells treated with aurantium serrata (p < 0.02) and cells treated with Gleevec ( Figure 5A , lower left figure). Therefore, at a concentration of 2.5 μM, aurantium flavonoids significantly inhibited the proliferation of breast cancer cell lines. Therefore, compound IV is also considered to exhibit similar inhibitory behavior.
[0131] Previous studies have shown that phosphorylated CrkL inhibits immune cell function. It was then assessed whether pCrkL inhibitors could restore immune cell function. To test this, IL-2 production by human PBMCs treated with different concentrations of aurantiacum was quantified. Phytohemagglutinin (PHA) was used to stimulate IL-2 secretion as a positive control group. Compared to DMSO from the first donor (vehicle group), a decrease in IL-2 production was observed in PBMCs treated with aurantiacum and Gleevec. However, no difference was observed between aurantiacum and Gleevec treatment ( Figure 5B , upper right). No differences were observed between DMSO and Gleevec, DMSO and aurantiacum, and between Gleevec and aurantiacum from the second donor ( Figure 5B , middle). Similar results were obtained from a third donor ( Figure 5B , figure below).
[0132] In summary, although aurantiacum did not enhance normal immune cell function, it also did not inhibit immune cell function; therefore, these data suggest that aurantiacum alone inhibits breast cancer cell line proliferation but may not have any detectable effect on immune cell function using IL-2 as a readout.
[0133] To further elucidate the specificity of the killing effect of aurantiacum on breast cancer cells rather than immune cells, the MTT proliferation assay was used to calculate the percentage survival rates among breast cancer cells, PBMCs from healthy donors, HCC-HepG3 cells and leukemia cells under treatment with different concentrations of aurantiacum.
[0134] Auricularia serrata can not only inhibit the cell proliferation of breast cancer cells, but also has a significant growth inhibitory effect on other solid tumor HCC HepG2 cells. HepG2 cells were treated with various concentrations of auricularia serrata for 48 hours, and the proliferation of HepG2 cells began to be significantly inhibited at 1 μM ( Figure 5C ). These results suggest that auranthus flavonoids have a wide range of potential uses against various tumor cell lines in addition to breast cancer cells.
[0135] Different subtypes of breast cancer were included in the assay, including non-triple negative breast cancer (non-TNBC) cell lines (MCF7 and MDA-MB-453) and TNBC (MDA-MB-231, MDA-MB-231-GFP-LUC, Hs578t, and MDA-MB-468) cell lines ( Figure 5D ). The average percent survival of PBMCs from four different healthy donors was significantly higher than that of breast cancer cell lines treated with different concentrations of aurantiacum. Meanwhile, the IC50 for breast cancer cells ranged from 1.3 to 3.6 μM and was >18 μM in PBMCs, indicating the specificity of aurantiacum in inhibiting breast cancer cell survival and further suggesting that compound IV would exhibit similar behavior.
[0136] To further test the specificity of the inhibition of aurantia serrata against specific breast cancer cell lines, the percentage survival rates between different hematopoietic cancer cell lines and healthy PBMCs were compared. K562, NK92-MI, Daudi, KHYG-1, PBMCs, and MDA-231-GFP-LUC cells were treated with 5 μM aurantia serrata for 3 days. The hematopoietic cancer cell lines (K562, NK92-MI, Daudi, and KHYG-1) and normal PBMCs were more resistant to inhibition by aurantia serrata than the MDA-MD-231-LUC breast cancer cell line, which was the most sensitive cell to aurantia serrata treatment ( Figure 5E ). The data show that aurantium flavonoids have a better killing effect on breast cancer cells than on hematopoietic cancer cells ( Figure 5E ). In conclusion, the natural compound aurantium flavonoids can specifically inhibit breast cancer cell proliferation in vitro.
[0137] In view of the obtained data of orange mulberry flavonoids, compound II, compound III and compound I ( Figure 6 ) to measure biological activity against various tumor cells.
[0138] In order to compare the killing effect of compound II and NC5, the percentage survival rate between breast cancer cells MDA-MB-231 and PDAC cells BXPC3 treated with different concentrations of compound II was compared using MTT proliferation assay. In some embodiments, compound II shows a killing effect comparable to NC5 in MDA-MB-231 cells ( Fig. 7A In BXPC3 cells, compound II has a stronger killing effect than 5uM NC5 ( Figure 7B The killing effect was further confirmed by propidium iodide staining of BXPC3 cells treated with various concentrations of NC5 or compound II ( Figure 7C ). Compound II Figures 7A-7C It is called "NC5-SO2F".
[0139] Compound embodiments, compound III and compound I were also prepared and evaluated. TNBC cells and PDAC cells were treated with a series of doses of original NC5 and modified NC5 derivatives for 24 hours and 48 hours. Cell viability was measured by XTT assay. Both compound III and compound I had toxic effects comparable to NC5 in MDA-MB-231 cells ( Fig. 8A ). When used with BXPC3( Figure 8B ) and Sk-Hep1 cells ( Figure 8C ), they also showed better toxic effects than NC5. Figures 8A-8CIn the present invention, compound III is referred to as "NC5-140-1" and compound I is referred to as "NC5-140-2".
[0140] To further test the in vivo specificity of NC5, a breast cancer cell line xenograft model was used. Several groups have used orthotopic xenograft TNBC animal models using MDA-MB-231-GFP-LUC cells to demonstrate efficacy in vivo tumor suppression. Specifically, MDA-231-GFP-LUC cells expressing luciferase and GFP were implanted into NSG TM The initial tumor establishment was confirmed by bioluminescence imaging using an in vivo imaging system (IVIS) 6 days after tumor cell implantation. After confirmation, the mice were randomly divided into three treatment groups: (1) vehicle control group (0.5% ), (2) Gleevec treatment group, (3) Aurora serrata treatment group. The vehicle control group was given by oral gavage at 0.5% The Gleevec treatment group was treated with a dose of 40 μg / g body weight, and the auranthus serratus flavonoids treatment group was treated with a dose of 5.0 μg / g body weight. The auranthus serratus flavonoids treatment dose for the auranthus serratus flavonoids treatment group was based on previous literature, which showed that 0.5% A dose of 5 mg / kg / day achieved cardioprotection and improved ventricular function. This example also describes an in vivo titration analysis showing that a dose range of 3.125-6.25 mg / kg / day significantly inhibited breast cancer growth in mice (data not shown).
[0141] In the MDA-MB-231-GFP-LUC orthotopic xenograft model, a treatment dose of 5.0 mg / kg / day of aurantia serrata was used, compared to a dose (40 mg / kg / day) of 8 times the current FDA-approved drug Gleevec (also known as imatinib mesylate). It was observed that 5.0 mg / kg / day of aurantia serrata significantly inhibited the growth of MDA-MB-231 tumors in mice in a once-daily oral delivery regimen, which represents the most aggressive TNBC subtype ( Fig. 9A ). Low-dose aurantium treatment also prolonged mouse survival compared to vehicle control and Gleevec treatment groups with an 8-fold higher dose. Fig. 9B As shown, the median survival days of the aurantiacum flavonoids-treated group (41 days) were 1.6 times longer than those of the vehicle control group (25 days) and 1.4 times longer than those of the Gleevec-treated group (28 days).
[0142] To quantify the toxicity of aurantiacum odoratum, the body weight of mice was monitored throughout the drug treatment until the terminal stage (between 23 and 27 days, Fig. 9C), no significant differences were observed among the three treatment groups. The increased differences in body weight among the groups after day 23 were caused by the larger tumor growth in vehicle- and Gleevec-treated mice (each tumor weighed 1.8-2 g, data not shown).
[0143] In conclusion, low-dose aurantium flavonoids treatment significantly inhibited MDA-MB-231 tumor growth in vivo without obvious side effects.
[0144] To further confirm that breast cancer cell line models can recapitulate human breast cancer models, patient-derived xenograft (PDX) models were used, as aurantiacum treatment effectively inhibited MDA-MB-231 tumor growth in mice. To determine the in vivo inhibitory efficacy of aurantiacum in TNBC clinical patient tumors, aurantiacum was evaluated in the presence of aurantiacum in a PDX Live TM Therapeutic efficacy of the library in patient-derived tumor xenograft mice. TM00089 breast invasive ductal carcinoma was selected, characterized by TNBC ER - / PR - / HER2 - , BRCA1 V757fs , because TNBC tumors with BRCA1 mutations are often the most aggressive and have the worst prognosis within the first five years after diagnosis compared with other types of breast cancer. Consistent with previous results in TNBC cell-bearing mice, TNBC patient-derived tumor growth was significantly more inhibited in mice treated with 5.0 μg / g aurantiacum than in mice treated with vehicle controls ( Fig.9D ).
[0145] The median survival of mice treated with aurantium tinctorium (53 days) was 1.4 times longer than that of vehicle controls (39 days, p = 0.0025). Fig.9E There was no significant difference in body weight between vehicle- and Aurora serrata-treated mice during drug treatment ( Fig.9F These results indicate that aurantiacum treatment can effectively inhibit TNBC growth in two different xenograft breast cancer models (MDA-MB-231 cells and TNBC patient tumor segments).
[0146] To further test whether the tumor growth inhibitory effect of NC5 is applicable to other solid tumors, HCC-Sk-Hep1 cell line and PDAC-BXPC3 cell line xenograft models were used. 1.5×10 6SK-Hep1 or BXPC3 cells, 6-10 days after tumor cell injection, palpable tumors in NSG mice were confirmed. After confirmation, the mice were randomly divided into two treatment groups: (1) vehicle control group (0.5% Avicel), (2) aurantia odoriferum treatment group. The vehicle control group was treated with 0.5% Avicel and the aurantia odoriferum treatment group was treated with 5.0 μg / g body weight by oral gavage.
[0147] Tumor size and body weight were measured every 3-4 days. Oral administration of 5.0 μg / g / day of aurantiacum inhibited Sk-Hep1 and BXPC3 tumor growth in mice, similar to the TNBC tumor model ( Fig. 10A and 10C In both xenograft models, aurantiacum treatment also prolonged mouse survival compared to those treated with vehicle controls ( Fig. 10B and 10D In the Sk-Hep1 tumor model, the median survival of mice treated with aurantiacum serrata (37 days) was 1.54 times longer than that of vehicle controls (24 days, p = 0.0045). In the BXPC3 tumor model, the median survival of mice treated with aurantiacum serrata (43.5 days) was 1.2 times longer than that of vehicle controls (37 days, p = 0.0025).
[0148] To test the effects of the disclosed compounds on xenograft mouse models, an HCC-Sk-Hep1 cell line xenograft model was used in NSG mice and a 4T1-Luc orthotopic syngeneic breast tumor model was used in Balb / c mice. Palpable tumors in NSG or Balb / c mice were identified. The mice were then randomly divided into four treatment groups: (1) vehicle control group (0.5% Avicel), (2) NC5, 5.0 μg / g, (3) Compound III, 5.0 μg / g, (4) Compound I, 5.0 μg / g; Balb / c mice were divided into three groups: (1) vehicle control group (0.5% Avicel), (2) NC5, 5.0 μg / g, (3) Compound III, 5.0 μg / g, administered by oral gavage, the vehicle control group was treated with a dose of 0.5% Avicel, and the treatment group was treated with a dose of 5.0 μg / g body weight. Figures 11A-11C In the present invention, compound III is referred to as "NC5-140-1" and compound I is referred to as "NC5-140-2".
[0149] Tumor size and body weight were measured every 3-4 days. There was no significant difference in the body weight of mice in the treatment group and the control group (data not shown). Oral administration of NC5 and the compound embodiments of the present disclosure did not show significant differences in tumor size before day 25 of inoculation of Sk-Hepl tumor cells. Inhibition of tumor growth was observed in all treatment groups compared to the control group ( Fig.11A In the Sk-Hep1 tumor model, the median survival of mice treated with NC5 (34 days), compound III (34.5 days), and compound I (28.5 days) was longer than that of the vehicle control (26 days).
[0150] In the orthotopic syngeneic 4T1 mammary fat pad Balb / c model, stable growth inhibition was observed with NC5 and compound III ( Fig. 11C In the 4T1 / Balb / c tumor model, the median survival of mice treated with NC5 (38.5 days) and compound III (39.5 days) was significantly longer than that of vehicle controls (25 days, p=0.002) ( Fig.11D In conclusion, compound III is a promising anticancer compound for solid tumors.
[0151] Alanine aminotransferase (ALT, SGPT), aspartate aminotransferase (AST, SGOT), blood urea nitrogen (BUN), and creatinine levels were examined to determine the in vivo liver and kidney toxicity of aurantia serrata treatment. Mice were treated with low-dose aurantia serrata (5 μg / g) or high-dose aurantia serrata (20 μg / g) and treated with Gleevec (imatinib mesylate, 40 μg / g) and vehicle (0.5% Avicel). The high-dose (20 μg / g) aurantia serrata treatment group showed a slight increase in ALT ( Fig. 12A ), AST decrease ( Fig. 12B ) and slightly elevated blood urea nitrogen (BUN) levels ( Fig. 12C ). However, these changes were of no physiological significance, as ALT, AST, and BUN levels in all mice were within the normal mouse reference range. Creatinine blood levels in all four treatment groups were less than 0.2 mg / dl ( Fig.12D ).
[0152] In summary, these results suggest that treatment with aurantiacum and Gleevec at the indicated doses caused little or no damage to the liver or kidneys during treatment in mice.
[0153] The specificity of aurantia serrata for CrkL was demonstrated. The intracellular pCrkL levels of breast cancer cell lines were examined between aurantia serrata treated groups and vehicle control groups. As expected, aurantia serrata treated MDA-MB-231-LUC cells had reduced intracellular pCrkL levels compared to vehicle treated cells by flow cytometry analysis ( Fig.13AAfter treatment with nerolidol, there was no significant difference in the total expression of CrkL ( Fig.13A , middle group).
[0154] To investigate the different responses of tumor or normal cells to NC5, the basal protein levels of pCrkL and CrkL were measured by Western blotting of MDA-231, MDA-468, and HepG2 cells. PBMC cells from normal donors were used as comparison. Tumor cells have much higher basal levels of pCrkL than normal PBMC, which may be the basis for the specific inhibition of pCrkL by NC5 ( Fig. 13B ).
[0155] The cytotoxic effects of aurantiacum on breast cancer cells were characterized. Breast cancer cells treated with aurantiacum were stained with the Annexin V / PI kit and measured by flow cytometry. The experiment was repeated at least three times in MDA-MB-231, MDA-MB-468 and PBMC cells. After 24 hours of treatment of MDA-MB-468 cells with 10uM NC5, the percentage of apoptotic cells increased significantly. PBMC cells showed limited response to NC5 treatment ( Fig. 13C The apoptotic effects of NC5 in MDA-231 and MDA-468 cells are summarized in the bar graph; even low concentrations of NC5 (1uM) significantly induced apoptosis in TNBC ( Fig.13D ).
[0156] To investigate the molecular mechanism of aurantium tinctorium-induced apoptosis in breast cancer cells, MDA-231, MDA-468, and PBMC cells were treated with NC5 (1uM, 5uM, and 10uM) for 24 hours. Cell proliferation was first determined by MTT assay as confirmation. NC5 significantly inhibited cell proliferation in MDA-231 and MDA-468 cells, but there was no statistical difference in PBMC isolated from normal donors ( Fig.14A ). Protein levels of pCrkL, CrkL, cell proliferation and apoptosis related targets were then determined by Western blotting. NC5 treatment significantly inhibited pCrkL levels. CrkL is known to mediate activation of Raf / ERK and PI3K pathways. Therefore, proteins associated with these two pathways were utilized. Inhibition of pCrkL reduced P-ERK1 / 2 levels in breast cancer cells compared to minimal changes in PBMCs.
[0157] The levels of apoptosis-related proteins pJNK and BIM were also determined, and NC5 significantly increased the levels of these proteins, which was associated with enhanced apoptosis in cancer cells ( Fig. 14B). β-actin was used as a control to normalize the loading. The integrated density value (IDV) of each band was measured and shown below each blot. These data indicate that ERK1 / 2 and BIM are key target proteins associated with the inhibition of pCrkL by aurantiacum serrata. Inhibition of pCrkL disrupts the balance of cell proliferation and death in triple-negative breast cancer cells by regulating these signal transduction pathways ( Fig.15 The differential expression of these proteins in TNBC vs. normal immune cells makes aurantium and the compounds disclosed herein candidates for cancer treatment.
[0158] Example 3
[0159] In this example, solubility measurements were performed using a phosphate buffer (also referred to as "PB") system and a water system to assess thermodynamic solubility. The pH of the PB system was 7.4 to simulate the in vivo environment. For the PB system, the values were determined as NC5: thermodynamic solubility pH = 7.4 < 0.42 μg / mL; Compound III: thermodynamic solubility pH = 7.4 < 0.48 μg / mL; Compound I: thermodynamic solubility pH = 7.4 < 0.48 μg / mL. The results of the water assay are as follows: NC5: thermodynamic solubility water < 0.42 μg / mL; Compound III: thermodynamic solubility water < 0.48 μg / mL; Compound I: thermodynamic solubility water < 0.48 μg / mL.
[0160] Example 4
[0161] In this example, Sk-Hep1 cells were pretreated with 50uM H2O2 for 1 hour to induce pCrkL activation and then incubated with 10uM NC5 or Compound III for 24 hours. pCrkL (T207) expression was determined by flow cytometry. Both NC5 and Compound III inhibited the pCrkL protein level induced by H2O2 in Sk-Hep1 cells, as shown in Figure 2. Fig.16 shown.
[0162] Example 5
[0163] In this example, the activity of NC5 on PBNK and CD147-CAR-NK killing in BXPC3 cells was evaluated. PBNK or CD147-CAR-NK cells were incubated with 1uM NC5 overnight, and then the cells were harvested for Cr51 release assay to examine cytotoxicity. Fig.17A and 17B As shown, NC5 was observed to increase the expression of PBNK in BXPC3 cells ( Fig.17A ) and CD147-CAR-NK( Fig. 17B) Killing. Asterisks indicate significance of vehicle vs. NC5 at the indicated E:T ratios. *p<0.05, **p<0.01, n=3.
[0164] Example 6
[0165] In this example, the activity of NC5 and compound III on the killing activity of PBNK cells against MDA-MB-231 and SK-Hep1 was evaluated. PBNK cells were incubated with 1uM NC5 or compound III overnight, and then the cells were harvested for Cr51 release assay to examine cytotoxicity. Fig.18A and 18B As shown, NC5 and compound III increased the expression of PBNK cells against MDA-MB-231 ( Fig.18A ) and SK-Hep1( Fig.18B ) killing activity. Asterisks indicate significance of vehicle control vs. NC5 at the indicated E:T ratios. *p<0.05, **p<0.01, n=3.
[0166] Example 7
[0167] In this example, the activity of NC5, compound III, and the known chemotherapeutic agent cytarabine in an AML cell line (MoLM-13) was evaluated. MoLM-13 cells were collected and seeded at 5,000 cells / well in a 96-well plate. The cells were incubated for 24 hours, and then DMSO control or various concentrations of the drug were added. After another 48 hours of incubation, 3uL CCK-8 was added to each well and incubated at 37°C for 3 hours. The absorbance at 460nm was measured in a microplate reader. AML cells treated with various concentrations (1uM, 5uM, 10uM) of NC5 and compound III showed reduced cell viability via CCK-8 assay. The relevant absorbances were normalized and plotted as a line graph. The p-values were determined by a two-tailed Student's t-test (*=p<0.5, **=p<0.01, ***=p<0.001). As shown Fig.19A As shown, compound III significantly reduced the cell viability of AML tumor cell lines at different concentrations.
[0168] Example 8
[0169] In this example, the activity of NC5, compound III, and the known chemotherapeutic agent sorafenib was evaluated in HepG2, SKHep1, Huh7, and MDA468 cell lines. Cells from each cell line were collected and seeded at 5,000 cells / well in a 96-well plate. The cells were incubated for 24 hours, and then DMSO control or various concentrations of the drug were added. After another 48 hours of incubation, 3uL CCK-8 was added to each well and incubated at 37°C for 3 hours. The absorbance at 460nm was measured in a microplate reader. Cells from each cell line were treated with various concentrations (1uM, 5uM, 10uM) of NC5 and compound III. The relative absorbances were normalized and plotted as a line graph. The p-values were determined by a two-tailed Student's t-test (*=p<0.5, **=p<0.01, ***=p<0.001). As shown Figures 19B-19E As shown, compound III significantly reduced the cell viability of each cell line at different concentrations.
[0170] In view of the many possible embodiments to which the principles of the present disclosure may be applied, it should be recognized that the embodiments shown are only preferred embodiments of the present disclosure and should not be considered to limit the scope of the present disclosure. Instead, the scope is defined by the appended claims. Therefore, we claim protection for all inventions that fall within the scope and spirit of these claims.
Claims
1. A compound selected from:
2. The compound according to claim 1, wherein the compound is 3. The compound according to claim 1, wherein the compound is 4. The compound according to claim 1, wherein the compound is 5. The compound according to claim 1, wherein the compound is 6. The compound according to claim 1, wherein the compound is 7. A therapeutically effective composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
8. The therapeutically effective composition according to claim 7, wherein the compound is 9. The therapeutically effective composition according to claim 7, wherein the compound is 10. The therapeutically effective composition according to claim 7, wherein the compound is 11. The therapeutically effective composition according to claim 7, wherein the compound is 12. The therapeutically effective composition according to claim 7, wherein the compound is 13. The compound according to claim 1, for use in inhibiting or preventing tumor cell growth without inhibiting immune cell function.
14. A method of inhibiting a Crk-mediated signaling pathway, comprising exposing a sample or an individual to a compound according to claim 1 or a therapeutically effective composition thereof.
15. The method of claim 14, wherein the sample is an in vitro or ex vivo sample.
16. The method of claim 14, wherein the compound inhibits proliferation of tumor cell lines but does not inhibit immune cell function.
17. A method of enhancing immune cell responses in an individual suffering from or suspected of suffering from a chronic viral infection or cancer, comprising administering to the individual a compound according to claim 1 or a therapeutically effective composition thereof.
18. The method of claim 17, wherein the compound is 19. The method of claim 17, wherein the compound is 20. The method of claim 17, wherein the compound is 21. The method of claim 17, wherein the compound is 22. The method of claim 17, wherein the compound is
